Obrixtamig + Chemotherapy for Carcinoid Tumor

This trial examines whether a new treatment, obrixtamig, combined with standard chemotherapy, can extend the lives of people with advanced extrapulmonary neuroendocrine cancer. Obrixtamig is a unique molecule that may enhance the immune system's ability to fight cancer. Participants will be randomly assigned to two groups: one receiving obrixtamig with chemotherapy (carboplatin and etoposide) and the other receiving only chemotherapy. The study also tests a device that measures a tumor marker called DLL3. This trial may suit those with advanced neuroendocrine cancer who have not undergone certain previous treatments. As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking cancer treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss your specific situation with the trial coordinators or your doctor.

A previous study found that the combination of obrixtamig and chemotherapy was generally well-tolerated by patients, with no unexpected harmful effects reported. Patients did not experience overlapping side effects, suggesting the treatment may be safe. Other research has also shown that obrixtamig does not cause unexpected harmful effects when combined with other cancer drugs.

Researchers are excited about Obrixtamig for carcinoid tumors because it introduces a novel approach by combining with traditional chemotherapy agents like carboplatin and etoposide. Unlike current treatments that primarily focus on slowing tumor growth, Obrixtamig is designed to enhance the immune system's ability to target and destroy cancer cells. This new mechanism of action offers the potential for improved treatment outcomes, making it a promising addition to the existing standard of care.

This trial will compare the effectiveness of adding obrixtamig to the usual chemotherapy drugs, carboplatin and etoposide, for treating extrapulmonary neuroendocrine cancer. Research has shown that patients who received this combination had a median progression-free survival of 7.6 months, meaning their cancer did not worsen for that time, compared to 5.1 months for those who only had chemotherapy. This suggests that obrixtamig might help delay cancer progression. Additionally, 64% of patients on the combination treatment did not experience cancer progression for at least 6 months. These findings indicate that obrixtamig could enhance the effectiveness of standard chemotherapy.¹²⁶⁷⁸